发明授权
US4051237A Glycopeptide antibiotics Bu-2231 A and B and process for producing same
失效
GLYCOPEPTIDE抗生素BU-2231A和B及其生产方法
- 专利标题： Glycopeptide antibiotics Bu-2231 A and B and process for producing same
- 专利标题（中）： GLYCOPEPTIDE抗生素BU-2231A和B及其生产方法
-
申请号： US608494申请日： 1975-08-28
-
公开(公告)号： US4051237A公开(公告)日： 1977-09-27
- 发明人: Hiroshi Kawaguchi , Koji Tomita , Hiroshi Tsukiura , Masataka Konishi
- 申请人： Hiroshi Kawaguchi , Koji Tomita , Hiroshi Tsukiura , Masataka Konishi
- 申请人地址： NY New York
- 专利权人： Bristol-Myers Company
- 当前专利权人： Bristol-Myers Company
- 当前专利权人地址： NY New York
- 主分类号： C12P1/06
- IPC分类号： C12P1/06 ; A01N63/02 ; A61K35/74 ; A61P31/04 ; C07G11/00 ; C07K9/00 ; C12P1/04 ; C12P21/00 ; C12R1/465 ; F16J15/38
摘要：
A novel water-soluble basic glycopeptide antibiotic complex designated herein as Bu-2231 is produced by fermentation of a Bu-2231-producing strain of Streptoalloteichus hindustanus. Complex Bu-2231 and two of its major components designated herein as Bu-2231 A and B are found to inhibit the growth of various Gram-positive and Gram-negative and acid-fast bacteria as well as certain plant pathogens. The complex and components Bu-2231 A and B are also useful in inhibiting the growth of various tumors in rodents, for example, Walker 256 carcinosarcoma and Lewis Lung carcinoma.